Phreesia, Inc. (PHR) Stock Price & Analysis

Phreesia, Inc. (PHR) is trading at USD 12.32, down 1.91% today, as of November 18, 2026 at 20:57 UTC (US market open; quotes may be delayed), according to Nexqual market data.

PHR last closed at USD 12.56; today's session has ranged USD 12.04–12.95 on volume of 679,082 shares. Market capitalization is $764.71M, with a 52-week range of USD 7.77–21.24 (NYQ). Source: Nexqual, retrieved November 18, 2026 at 20:57 UTC.

Also available as compact Markdown for AI agents: nexqual.com/PHR.md

Key facts (PHR)

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PHR)

USDFY2022FY2023FY2024FY2025FY2026TTM
Revenue$213M$281M$356M$420M$481M$508M
Operating income-$117M-$177M-$136M-$58.1M-$6.6M$12.5M
Net income-$118M-$176M-$137M-$58.5M$2.3M$10.4M
EPS (diluted)-$2.37-$3.36-$2.51-$1.02$0.04—
Free cash flow-$93.1M-$94.9M-$38.2M$23.7M$67.7M$80.7M
Operating margin-54.8%-62.9%-38.3%-13.8%-1.4%2.5%
Net margin-55.4%-62.7%-38.4%-13.9%0.5%2.1%
Revenue growth+43.4%+31.7%+26.8%+17.8%+14.5%—
Cash + short-term investments$314M$177M$87.5M$84.2M$73.8M—
Total debt$360K$246K$3.1M$1.9M$2.7M—

Fiscal years end Jan. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jul 31, 2026) (PHR)

P/E 73.2x · P/E ex non-operating (est.) ≈37.8x · P/S 1.5x · EV/EBITDA 13.9x · EV/Sales 1.4x · P/FCF 9.5x · P/B 2.1x · FCF yield 10.56% · Earnings yield 1.37% · Net cash $73.5M · EV $691M

P/E at fiscal year-ends: Jan 2026 358.1x.

Insider sales (SEC Form 4, open-market, last ~7 months) (PHR)

6 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

Trade dateInsiderRoleSharesValue% of holdings sold10b5-1 planInsider type
2026-09-21Hoffman Allison CGeneral Counsel & Secretary6,662$67K2.4%Yes (adopted December 19, 2025)Routine (sold in Jan & Apr & Sep & Oct each year 2023–2025)
2026-07-16Hui YvonnePrincipal Accounting Officer1,247$14K5.4%Yes (adopted January 15, 2026)Too little history (no open-market trades in 2023)
2026-07-14Egbuonu-Davis LisaDirector536$6K1.4%Yes (adopted December 16, 2025)Too little history (no open-market trades in 2023)
2026-07-06Hui YvonnePrincipal Accounting Officer1,371$15K5.4%Yes (adopted January 15, 2026)Too little history (no open-market trades in 2023)
2026-06-25Egbuonu-Davis LisaDirector2,546$24K6.2%Yes (adopted December 16, 2025)Too little history (no open-market trades in 2023)
2026-05-18Hui YvonnePrincipal Accounting Officer431$4K1.8%Yes (adopted January 15, 2026)Too little history (no open-market trades in 2023)

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (PHR)

Consensus Buy (mean 2.44 on a 1–5 scale), 18 analysts; mean target USD 13.87 (low 10, high 19).

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-11-11JP MorganDowngradeNeutral → Underweight$13
2026-10-12BarclaysTarget raisedEqual-Weight$10 → $11
2026-09-08Raymond JamesDowngradeOutperform → Market Perform
2026-09-04DA DavidsonTarget loweredBuy$14 → $13
2026-09-04BairdTarget raisedNeutral$10 → $11
2026-09-03Freedom Capital MarketsMaintainedBuy$14
2026-09-03RBC CapitalReiteratedOutperform$19
2026-09-03Wells FargoTarget raisedEqual-Weight$9 → $10
2026-09-03Canaccord GenuityMaintainedBuy$16
2026-09-03NeedhamReiteratedBuy$14
2026-08-31NeedhamReiteratedBuy$14

Total return (dividends reinvested) (PHR)

1Y (from 2025-11-18)5Y (from 2021-11-15)
Total return-37.1%-81.8%
S&P 500 (SPY)+11.8%+66.5%
Per year-37.2%-28.9%
Volatility (annualized)61.9%60.2%
Max drawdown-60.9% (Nov 2025→Apr 2026)-88.1% (Nov 2021→Apr 2026)

Dividends (PHR)

PHR paid no cash dividend in the last five years.

Short interest (PHR)

3,021,990 shares sold short, 5.99% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 3,015,320 shares (+0.2%). Days to cover: 4.6 (short shares ÷ average daily volume).

PHR earnings history and stock reaction

Results filedQuarterEPSConsensusSurpriseStock reaction
—Quarter ended Jul 31, 2026$0.28$0.32Miss −12.5%—
—Quarter ended Apr 30, 2026$0.27$0.29Miss −6.9%—
—Quarter ended Jan 31, 2026$0.44$0.32Beat +37.5%—
—Quarter ended Oct 31, 2025$0.31$0.24Beat +29.2%—

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

PHR recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 13, 2026Schedule 13G/AAQR Capital Management, LLC, AQR Capital Management Holdings, LLC: 4.3% of shares, passive 5%+ holder (amended)
Oct 27, 2026Schedule 13GBlackRock Portfolio Management LLC: 5.1% of shares, passive 5%+ holder
Sep 3, 202610-QQuarterly report · period ended Jul 31, 2026
Sep 2, 20268-KQuarterly results
Aug 12, 2026Schedule 13GAQR Capital Management, LLC, AQR Capital Management Holdings, LLC: 5.1% of shares, passive 5%+ holder

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

PHR suppliers, customers and competitors (named in its 10-K)

RelationshipCompanySentence in the filing
PartnerVisa (V)“We have developed partnerships with primary credit card processors in the United States to facilitate payment processing, and we are registered with Visa, MasterCard, American Express, Discover and other card networks as a service provider (payment facilitator or the equivalent) for acquiring member institutions.”

Quoted from the company's 10-K filed Mar 31, 2026.

PHR company outlook (results filed Sep 2, 2026)

Quoted word-for-word from the SEC 8-K results press release.

PHR analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Oct 2026)$0.35$0.36-0.2%$128.4M10
Next quarter (ends Jan 2027)$0.35$0.37-5.5%$126.9M10
Current fiscal year (ends Jan 2027)$1.26$1.33-4.9%$515.7M10
Next fiscal year (ends Jan 2028)$1.58$1.61-1.6%$534.6M9

Key Statistics (as of November 18, 2026 at 20:57 UTC)

PriceUSD 12.32
Change▼ 1.91% (down)
Previous CloseUSD 12.56
OpenUSD 12.42
Day RangeUSD 12.04 – 12.95
52-Week RangeUSD 7.77 – 21.24
Volume679,082 shares
Market Cap$764.71M
ExchangeNYQ

Technical Analysis (PHR)

Nexqual's technical model rates PHR "NEUTRAL" based on 3 bullish and 2 bearish signals across 129 daily candles, as of November 18, 2026 at 20:57 UTC.

Overall SignalNEUTRAL
RSI (14)54.23 (neutral)
vs SMA50Above (USD 11.35)
MACD0.32 (positive)

Analyst Ratings (PHR)

Wall Street analysts rate PHR "Buy" based on 18 analysts, with a mean price target of USD 13.87 (range USD 10–19), per Nexqual as of November 18, 2026 at 20:57 UTC.

Consensus RatingBuy
Analyst Count18
Mean TargetUSD 13.87
High TargetUSD 19
Low TargetUSD 10
Buy / Hold / Sell10 / 7 / 1

Earnings (PHR)

Next Earnings Date2026-12-02
EPS EstimateUSD 0.35
Revenue Estimate$128.37M

Recent Earnings History

QuarterActual vs Estimate
2026-07-31USD 0.28 vs est 0.32 ▼ miss
2026-04-30USD 0.27 vs est 0.29 ▼ miss
2026-01-31USD 0.44 vs est 0.32 ▲ beat
2025-10-31USD 0.31 vs est 0.24 ▲ beat

Source: Nexqual, November 18, 2026 at 20:57 UTC.

Financials & Fundamentals (PHR)

Total Revenue$507.79M
Revenue Growth (latest quarter, YoY)+10.40%
Gross Margin+67.52%
Operating Margin+4.29%
Profit Margin+2.06%
ROE+3.12%
Debt / Equity0.18
Current Ratio1.76
Total Cash$72.94M
Total Debt$67.95M
Free Cash Flow (last four quarters to Jul 2026, SEC 10-Q / 10-K)$80.75M (15.9% of revenue)

Source: Nexqual, November 18, 2026 at 20:57 UTC.

Financial Health Score (PHR)

Nexqual rates Phreesia, Inc.'s overall financial health "Solid" across five dimensions, as of November 18, 2026 at 20:57 UTC.

GrowthSolid — Revenue +13% (last 4 quarters to Jul 2026 vs the 4 before, SEC)
ProfitabilityStrong — Gross margin 68%, operating 2% (last 12 months)
Balance SheetStrong — $75M cash and investments vs $1M debt (Jul 2026, SEC), net cash
Cash FlowStrong — FCF $81M (last 4 quarters to Jul 2026, SEC), 16% margin
EfficiencyWeak — ROE 3%, ROA 1.6% (last 4 quarters, SEC)

Ownership (PHR)

Insider Ownership+6.35%
Institutional Ownership+95.28%
Shares Outstanding62.07M
Float49.23M
Short % of Float+5.99%

Source: Nexqual, November 18, 2026 at 20:57 UTC.

Leadership (PHR)

Phreesia, Inc. is led by Chaim Indig, Co-Founder, CEO & Director, per Nexqual as of November 18, 2026 at 20:57 UTC.

Co-Founder, CEO & DirectorChaim Indig
Co-Founder & President of Provider SolutionsEvan Roberts
Chief Financial OfficerBalaji Gandhi
President of Network SolutionsDavid Linetsky
Chief Technology OfficerJack Callahan

Major Backers & Investors (PHR)

Notable institutional backers of Phreesia, Inc. include Pale Fire Capital SE, AQR Capital Management, LLC, Acadian Asset Management. LLC, according to Nexqual as of November 18, 2026 at 20:57 UTC.

Active Investors

InvestorStake
Pale Fire Capital SE14.38%
AQR Capital Management, LLC5.08%
Acadian Asset Management. LLC2.35%
Goldman Sachs2.31%
T. Rowe Price2.09%
Algert Global, LLC1.94%
Fidelity1.7%

Index Funds (Passive)

FundStake
BlackRock11.49%
Vanguard Group9.26%
State Street2.55%

Source: Nexqual, November 18, 2026 at 20:57 UTC.

From Phreesia, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

Legal & Regulatory Risks (Item 1A, quoted)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
HQYHealthEquity, Inc.USD 97.37▼ 4.39%
HSTMHealthStream, Inc.USD 26.93▼ 2.53%
OMDAOmada Health, Inc.USD 13.18▼ 6.43%
SOPHSOPHiA GENETICS SAUSD 7.47▲ 0.2%
NRCNRC HealthUSD 26.11▲ 0.87%
CARLCarlsmed, Inc.USD 17.32▼ 2.37%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:57 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt